Webdisclosure.com

SANOFI-AVENTIS (EPA:SAN)

26/03/2022 15:00

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

16/03/2022 11:18

Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

03/03/2022 08:00

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

01/03/2022 09:06

Annual Report 2021 Form 20F

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/02/2022 18:05

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/02/2022 18:00

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

23/02/2022 20:16

Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

23/02/2022 11:19

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

22/02/2022 19:14

Sanofi: Information concerning the total number of voting rights and shares - January 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

04/02/2022 23:00

FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease

Voir tous les communiqués de SANOFI-AVENTIS

«
1
2
3
4
5
6
7
8
9
10